Drug Type CAR-T |
Synonyms BCMA-CD19 CAR-T therapy(Peking University People's Hospital), BCMA-CD19 Targeted Chimeric Antigen Receptor T-Cell(Peking University People's Hospital) |
Target |
Action modulators |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | China | 26 Dec 2024 | |
| Antiphospholipid Syndrome | Phase 2 | China | 26 Dec 2024 | |
| Behcet Syndrome | Phase 2 | China | 26 Dec 2024 | |
| Immunoglobulin G4-Related Disease | Phase 2 | China | 26 Dec 2024 | |
| Myositis | Phase 2 | China | 26 Dec 2024 | |
| Scleroderma, Diffuse | Phase 2 | China | 26 Dec 2024 | |
| Sjogren's Syndrome | Phase 2 | China | 26 Dec 2024 | |
| Systemic Lupus Erythematosus | Phase 2 | China | 26 Dec 2024 | |
| Thrombotic Thrombocytopenic Purpura, Acquired | Phase 2 | China | 26 Dec 2024 |





